Clinical Trial Update: A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of solanezumab in prodromal Alzheimer's disease was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Solanezumab (LY2062430) (solanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-07-24